Follicular Lymphoma: Treating Early Progressors
Follicular Lymphoma: Treating Early Progressors
Case: A 62-Year-Old Male with Follicular Lymphoma
H & P:
- A 62-year-old man presents with lower abdominal discomfort and rapid weight loss over last 3 months
- PMH: Hypertension managed by statin
- PE: palpable inguinal lymphadenopathy
Diagnostic Work-Up
- Hematologic results
- ANC: 1200 /µL
- Platelets: 89,000 /µL
- β2-microglobulin: 3.5 mg/L
- Serum LDH: 230 IU/L
- Imaging: PET/CT reveals axillary and bilateral inguinal lymphadenopathy; 5 masses (~3cm each)
- Biopsy: FL, grade 2
- FLIPI status: High-risk
- Ann Arbor: Stage IV
- ECOG PS: 1
Treatment
- Patient treated with obinutuzumab + bendamustine
- Completed 6 cycles, achieved CR
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
August 16th 2024The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.
Read More
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
